Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Pasithea Therapeutics Corp. - 8-K, Current Report | 2 | SEC Filings | ||
11.06. | Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board | 1 | GlobeNewswire (USA) | ||
02.06. | Pasithea reports promising phase 1 results for cancer drug | 1 | Investing.com | ||
02.06. | Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025 | 100 | GlobeNewswire (Europe) | -- PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid tumors -- -- One patient in cohort 4A (15mg capsule) with stage 4 BRAF-mutated... ► Artikel lesen | |
20.05. | Pasithea Announces Strong Preclinical Results For PAS-004 In Inflammatory Disease Model | - | RTTNews | ||
20.05. | Pasithea's PAS-004 shows promise in inflammatory disease study | 1 | Investing.com | ||
20.05. | PAS-004 von Pasithea zeigt vielversprechende Ergebnisse in Studie zu Entzündungskrankheiten | 1 | Investing.com Deutsch | ||
PASITHEA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
20.05. | Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases | 3 | GlobeNewswire (USA) | ||
15.05. | Pasithea Therapeutics Corp. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
14.05. | Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site | 144 | GlobeNewswire (Europe) | -- First patient expected to be dosed during Q2 2025 ---- Trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in both plexiform neurofibromas and... ► Artikel lesen | |
07.05. | Pasithea Therapeutics Corp. - 8-K, Current Report | 3 | SEC Filings | ||
07.05. | Pasithea Therapeutics Announces Closing of $5 Million Public Offering | 4 | GlobeNewswire (USA) | ||
06.05. | Pasithea Therapeutics Announces Pricing of $5 Million Public Offering | 4 | GlobeNewswire (USA) | ||
06.05. | Pre-market Movers: Marin Software, Pasithea Therapeutics, China SXT Pharmaceuticals, Tactile Systems Technology, ThredUp | 501 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green Marin Software Incorporated (MRIN) is up over 141%... ► Artikel lesen | |
06.05. | Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results | 5 | Benzinga.com | ||
06.05. | Pasithea berichtet über vielversprechende Daten zu Krebsmedikament PAS-004 | 10 | Investing.com Deutsch | ||
06.05. | Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004 | 127 | GlobeNewswire (Europe) | -- PAS-004 shows up to 91% inhibition of pERK, confirming substantial target engagement -- -- One patient in cohort 4A with stage 4 KRAS G12R mutated pancreatic cancer achieves over 5 months of stable... ► Artikel lesen | |
01.05. | Pasithea Therapeutics Corp. - S-1, General form for registration of securities | 3 | SEC Filings | ||
29.04. | Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients | 219 | GlobeNewswire (Europe) | MIAMI, April 29, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic... ► Artikel lesen | |
25.04. | Pasithea Therapeutics Corp. - 8-K, Current Report | 1 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
OCUGEN | 0,892 | +0,47 % | Ocugen, Inc.: Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform... ► Artikel lesen | |
GENPREX | 1,820 | -100,00 % | Genprex, Inc. - 8-K, Current Report | ||
QIAGEN | 41,230 | +2,74 % | Biotech Report: Evotec rutschen ab, auch Qiagen verlieren | (shareribs.com) Frankfurt 19.06.2025 - Biotech-Aktien bewegen sich im deutschen Handel überwiegend nach unten. Evotec korrigieren dabei um mehr als drei Prozent. An der Wall Street findet wegen eines... ► Artikel lesen | |
EVOTEC | 7,196 | +0,50 % | Evotec-Aktie: Hop oder Top?! | © Foto: Symbolbild von Pilan FilmesDie Evotec-Aktie sorgt für Kopfschmerzen bei Anlegern. Nach einer kräftigen Erholung im Frühjahr zeigt sich das Papier des Hamburger Wirkstoffforschers wieder von... ► Artikel lesen | |
VOR BIOPHARMA | 1,060 | +93,96 % | Pre-market Movers: Vor Biopharma, Worthington Steel, Surf Air Mobility, Nano Labs, Protagenic Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).In the Green Vor Biopharma Inc. (VOR) is up over 109% at $1.16.
Worthington... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 46,990 | +0,04 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors | - If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors -
- Decision from European Commission expected in the third... ► Artikel lesen | |
BIONTECH | 90,40 | +0,67 % | Biotech Report: Biontech rutschen ab; Sektor an der Wall Street leichter | (shareribs.com) Frankfurt / New York 23.06.2025 - Biotech-Aktien zeigen sich im deutschen Handel überwiegend leichter. Unter anderem sacken Biontech kräftig ab. Auch an der Wall Street bewegt sich der... ► Artikel lesen | |
KYMERA THERAPEUTICS | 44,260 | -4,76 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
CUREVAC | 4,592 | -1,16 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,095 | -1,16 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 21,270 | -0,16 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target | ||
EDGEWISE THERAPEUTICS | 12,940 | -9,83 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
REGENCELL BIOSCIENCE | 21,320 | -2,02 % | Tesla, Regencell lead market cap stock movers this Monday | ||
VERVE THERAPEUTICS | 11,205 | -0,04 % | Lilly To Acquire Verve Therapeutics For One-Time Cardiovascular Treatments | ||
INSTIL BIO | 24,310 | -9,66 % | Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer | DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ("Instil") (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel cancer therapies, today announced... ► Artikel lesen |